Filing Flows › ADC Therapeutics SA (ADCT) › Q1 2025
ADC Therapeutics SA (ADCT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 14, 2025
ADC Therapeutics SA (ADCT) reported revenue of $23.0M for the first quarter 2025 (Q1 2025), +28% from a year earlier and +36% from the quarter before. Operating margin was -123.6%, net loss $38.6M (167.6% of revenue).
ADC Therapeutics SA, Q1 2025: revenue $23.0M (+28% year over year), operating margin -123.6%, net loss $38.6M, operating cash flow −$56.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $23.0M | +36% | +28% |
| Operating profit | −$28.5M | — | — |
| Net earnings | −$38.6M | — | — |
| Operating cash flow | −$56.3M | — | — |
What changed
Revenue was $23.0M in Q1 2025, up 28% year over year and up 36% from the previous quarter. Product revenues, net was the largest line at 76% of revenue. Royalties added $424K year over year (up 207%), 9% of the total change. Product revenues, net declined 2%.
Operating costs exceeded revenue by $28.5M, an operating margin of -123.6%. Total costs fell 0% while revenue rose 28%. The fastest-growing cost line was Research & development (+12%). The quarter ended with a net loss of $38.6M, wider than the previous quarter's $30.7M loss.
Operating cash flow was −$56.3M. Non-cash charges added back $342K of depreciation and $2.4M of share-based compensation. Working capital and other items used $20.5M. Capital expenditures of $264K exceeded it, leaving free cash flow of −$56.6M.
Questions
What was ADC Therapeutics SA's revenue in the first quarter 2025?
ADC Therapeutics SA (ADCT) reported revenue of $23.0M for the first quarter 2025 (Q1 2025), +28% from a year earlier and +36% from the quarter before.
Was ADC Therapeutics SA profitable in the first quarter 2025?
Operating loss was $28.5M (-123.6% of revenue) and net loss $38.6M.